CABIO(SH:688089)2024-10-28 08:41Financial Performance - The company's revenue for Q3 2024 was ¥126,315,510.03, representing a year-over-year increase of 0.20%[2] - The net profit attributable to shareholders for Q3 2024 was ¥16,001,222.04, a decrease of 37.42% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥12,555,040.31, down 31.24% year-over-year[2] - Basic earnings per share for Q3 2024 were ¥0.10, a decrease of 33.33% year-over-year[2] - The net profit attributable to shareholders for the year-to-date period increased by 38.86% compared to the same period last year, driven by higher revenue[6] - Net profit attributable to shareholders of the parent company was CNY 83,890,213.15, compared to CNY 60,414,285.96 in the previous year, marking an increase of 38.7%[17] - The company’s total comprehensive income for the period was CNY 81,174,237.89, compared to CNY 57,112,887.27 in the same period last year, an increase of 42.2%[19] Research and Development - The total R&D investment for Q3 2024 was ¥12,411,114.41, an increase of 19.61% compared to the same period last year, accounting for 9.83% of revenue[3] - Research and development expenses increased to CNY 34,296,787.91, compared to CNY 28,210,281.12, representing a growth of 21.6%[16] - Research and development expenses increased to ¥29,138,534.05 in the first three quarters of 2024, compared to ¥24,260,199.05 in the same period of 2023, reflecting a 20% increase[27] Assets and Liabilities - The company's total assets as of the end of Q3 2024 were ¥1,664,593,510.41, reflecting a 3.30% increase from the end of the previous year[3] - The company's total current assets amount to 672,288,659.48 RMB, a decrease from 708,777,769.17 RMB in the previous period[13] - Non-current assets total 992,304,850.93 RMB, compared to 902,714,862.84 RMB previously, showing an increase of approximately 9.93%[13] - Total liabilities increased to CNY 123,189,945.80 from CNY 117,601,481.29, indicating a rise of 4.5%[15] - The total liabilities of the company amounted to ¥184,245,091.24, an increase from ¥170,821,631.13 in the previous year[26] - The company's total equity reached ¥1,557,366,961.56, up from ¥1,503,874,633.61 in the previous year, indicating a growth of approximately 3.6%[26] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥105,805,187.55, a significant increase of 320.30% compared to the same period last year[6] - Operating cash inflow for the first three quarters of 2024 reached CNY 456.46 million, a 26.67% increase from CNY 360.42 million in the same period of 2023[21] - The net cash flow from operating activities for the first three quarters of 2024 was ¥106,241,108.31, significantly higher than ¥20,021,419.84 in the same period of 2023[30] - Cash flow from financing activities resulted in a net outflow of CNY 28.06 million, an improvement from a net outflow of CNY 42.10 million in the same period last year[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,578[9] - The largest shareholder, Wuhan Xiwang Biological Engineering Co., Ltd., holds 74,340,000 shares, accounting for 44.17% of total shares[9] - The company has not reported any significant changes in shareholder relationships or agreements among the top shareholders[10] Operational Insights - There are no applicable reminders for investors regarding the company's operational situation during the reporting period[11] - The company reported non-recurring gains of ¥3,446,181.72 for Q3 2024, with total non-recurring gains for the year-to-date period amounting to ¥18,328,079.96[5] - The company reported a decrease in other comprehensive income, with a net amount of CNY 12,019.08 compared to a loss of CNY 14,131.82 in the previous year[19] - The company recorded a significant increase in other income, which rose to ¥8,762,039.67 from ¥2,906,263.86 in the previous year[27]